How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chlamydial-pelvic-inflammatory-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Chlamydial pelvic inflammatory disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlamydial pelvic inflammatory disease (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chlamydial pelvic inflammatory disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Chlamydial pelvic inflammatory disease
Assistance Publique - Hôpitaux de Paris · 1 drug in Chlamydial pelvic inflammatory disease
Pfizer · 1 drug in Chlamydial pelvic inflammatory disease
Pfizer Inc. · 1 drug in Chlamydial pelvic inflammatory disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chlamydial pelvic inflammatory disease:

Cite this brief

Drug Landscape (2026). Chlamydial pelvic inflammatory disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chlamydial-pelvic-inflammatory-disease. Accessed 2026-06-11.

Chlamydial pelvic inflammatory disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing